Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08JPU
|
|||
| Former ID |
DNC002397
|
|||
| Drug Name |
G6976
|
|||
| Synonyms |
12H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-; Go 6976; 136194-77-9; GO6976; Go-6976; Goe 6976; UNII-B9IQO7JZ16; 6976; Go 6976, Solution; B9IQO7JZ16; 5,6,7,13-Tetrahydro-13-Methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile; CHEMBL302449; CHEBI:51913; 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole; 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole; Go6976
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H18N4O
|
|||
| Canonical SMILES |
CN1C2=CC=CC=C2C3=C4C(=C5C6=CC=CC=C6N(C5=C31)CCC#N)CNC4=O
|
|||
| InChI |
1S/C24H18N4O/c1-27-17-9-4-2-7-14(17)20-21-16(13-26-24(21)29)19-15-8-3-5-10-18(15)28(12-6-11-25)23(19)22(20)27/h2-5,7-10H,6,12-13H2,1H3,(H,26,29)
|
|||
| InChIKey |
VWVYILCFSYNJHF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 136194-77-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
618246, 7351424, 8032780, 8152223, 11120038, 11120526, 11121014, 11121726, 11122206, 11147121, 11362855, 11365417, 11367979, 11370921, 11370922, 11373580, 11376141, 14804486, 26756836, 26758817, 26758820, 29222633, 47364921, 47662012, 48184738, 49738156, 50064373, 50111446, 53788690, 57244622, 57269680, 57321842, 78828648, 85787769, 92310077, 99300989, 99302509, 99302681, 99431511, 103097512, 103249276, 103905532, 104303698, 117623470, 121365297, 125082057, 125767870, 129538596, 134339580, 134340061
|
|||
| ChEBI ID |
CHEBI:51913
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92. | |||
| REF 2 | Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8542-7. | |||
| REF 3 | The protein kinase C inhibitor G 6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003 Jan 1;63(1):31-5. | |||
| REF 4 | Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.